Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | MDH2 | P40926 | 1/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | LTA4H | P09960 | 3/20 | 0.53 |
| ▸ | PLA2G2A | P14555 | 3/20 | 0.53 |
| ▸ | HTR1D | P28221 | 3/20 | 0.51 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | CTSV | O60911 | 1/20 | 0.48 |
| ▸ | CTSL | P07711 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL273476 | 0.90 | TRPM8 (0.67) | IMPDH2TRPM8KDM4EMAPTLTA4H | |
| SCHEMBL27708665 | 0.82 | IMPDH2 (1.00) | IMPDH2ALDH1A1HPGDMDH2SMN1; SMN2 | |
| SCHEMBL1872950 | 0.81 | TRPM8 (0.81) | IMPDH2ALDH1A1HPGDMDH2SMN1; SMN2 | |
| SCHEMBL5664285 | 0.80 | IMPDH2 (0.56) | IMPDH2ALDH1A1HPGDMDH2SMN1; SMN2 | |
| SCHEMBL274611 | 0.80 | HTR1D (0.63) | IMPDH2ALDH1A1HPGDMDH2SMN1; SMN2 | |
| SCHEMBL4473938 | 0.80 | ALDH1A1 (0.65) | IMPDH2ALDH1A1HPGDMDH2SMN1; SMN2 | |
| SCHEMBL18103513 | 0.79 | HTR1B (0.50) | IMPDH2KDM4EMAPTHTR1DMEN1 | |
| SCHEMBL19412207 | 0.79 | KMT2A (0.61) | IMPDH2ALDH1A1HPGDMDH2SMN1; SMN2 | |
| SCHEMBL30354019 | 0.79 | KMT2A (0.61) | IMPDH2ALDH1A1HPGDMDH2SMN1; SMN2 | |
| SCHEMBL30354028 | 0.79 | KMT2A (0.61) | IMPDH2ALDH1A1HPGDMDH2SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230002394-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS, LTD. (GB) | 2023-01-05 | — | — | US | disclosed |
| US-10421759-B2 | Fused bicyclic compounds for the treatment of disease | AKARNA THERAPEUTICS, LTD. (GB) | 2019-09-24 | — | — | US | disclosed |
| US-20180118752-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | AKARNA THERAPEUTICS, LTD. | 2018-05-03 | — | — | US | disclosed |
| US-8524704-B2 | Azepinoindole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-8133992-B2 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2012-03-13 | — | — | US | disclosed |
| EP-1532153-B1 | AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | X CEPTOR THERAPEUTICS INC (US) | 2012-02-29 | — | — | EP | disclosed |
| US-20100173824-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20090326218-A1 | Azepinoindole and Pyridoindole Derivatives as Pharmaceutical Agents | EXELIXIS, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-7595311-B2 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | EXELIXIS, INC. (US) | 2009-09-29 | — | — | US | disclosed |
| US-7485634-B2 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | EXELIXIS, INC. (US) | 2009-02-03 | — | — | US | disclosed |
| EP-1692136-A2 | AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | X-Ceptor Therapeutics, Inc. (US) | 2006-08-23 | — | — | EP | disclosed |
| WO-2005056554-A2 | AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2005-06-23 | — | — | WO | disclosed |
| EP-1532153-A1 | AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | X-Ceptor Therapeutics, Inc. (US) | 2005-05-25 | — | — | EP | disclosed |
| US-20050054634-A1 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | AKARNA THERAPEUTICS, LTD. (GB) | 2005-03-10 | — | — | US | disclosed |
| US-20040023947-A1 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | X-CEPTOR THERAPEUTICS INC. | 2004-02-05 | — | — | US | disclosed |
| WO-2003099821-A1 | AZEPINOINDOLE AND PYRIDOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | X-CEPTOR THERAPEUTICS, INC. (US) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10421759-B2 | Fused bicyclic compounds for the treatment of disease | VHL, BRDT, PAICS | IMPDH2 1250/4885ALDH1A1 1592/4885HPGD 1072/4885 |
| US-20040023947-A1 | Azepinoindole and pyridoindole derivatives as pharmaceutical agents | HTR5A, MTNR1A, PTGDR | IMPDH2 1788/4885ALDH1A1 1722/4885HPGD 368/4885 |
| US-20100173824-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | HTR2A, HTR5A, HTR2C | IMPDH2 2523/4885ALDH1A1 1321/4885HPGD 550/4885 |
| US-20230002394-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | IMPDH2 1250/4885ALDH1A1 1592/4885HPGD 1072/4885 |
| US-20090326218-A1 | Azepinoindole and Pyridoindole Derivatives as Pharmaceutical Agents | HTR5A, MTNR1A, PTGDR | IMPDH2 1788/4885ALDH1A1 1722/4885HPGD 368/4885 |
| US-20050054634-A1 | Modulating active of receptors; therapy prevention of disease such aas symthrome X, antidiabetic agents, insulin resistance, hypoglycemic agents | GPR119, IRS1, INSR | IMPDH2 4365/4885ALDH1A1 3963/4885HPGD 3272/4885 |
| US-20180118752-A1 | FUSED BICYCLIC COMPOUNDS FOR THE TREATMENT OF DISEASE | VHL, BRDT, PAICS | IMPDH2 1250/4885ALDH1A1 1592/4885HPGD 1072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.